Drugs / Sarizotan
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00314288 | Jul 2002 → Jul 2003 | Parkinson disease, drug-induced dyskinesia | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT00009048 | Jan 2001 → Dec 2003 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02790034 | Oct 2016 → Aug 2019 | Rett syndrome | Newron Pharmaceuticals SPA | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00105521 | Sep 2004 → Mar 2006 | Parkinson disease, movement disorder | EMD Serono | Completed | No outcome recorded |
| Phase 3 | NCT00105508 | Sep 2004 → Feb 2006 | Parkinson disease, drug-induced dyskinesia | EMD Serono | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00310661 | Dec 2004 → Sep 2006 | tardive dyskinesia | Centre for Addiction and Mental Health | Terminated | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sarizotan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00314288 ↗ |
| Known as | EMD 128130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00009048 ↗ |
| Known as | EMD-77697 | ChEMBL registry synonym — accepted as the source's own label CHEMBL220808 ↗ |
| Known as | Sarizotan hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL220808 ↗ |
| Known as | SARIZOTAN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL220808 ↗ |
| Action | Activate | “a selective agonist of serotonin 5-HT1A receptors” NCT00009048 ↗4“Serotonin 1a (5-HT1a) receptor agonist” CHEMBL220808 ↗ “Dopamine D2 receptor partial agonist” CHEMBL220808 ↗ “Dopamine D3 receptor agonist” CHEMBL220808 ↗ “Dopamine D4 receptor agonist” CHEMBL220808 ↗ |
| Modality | Small molecule | — CHEMBL220808 ↗ |
| Route | Oral | “patients will begin taking either EMD 128130 tablets or capsules or a placebo” NCT00009048 ↗ |
| Target | DRD2 | “Dopamine D2 receptor partial agonist” CHEMBL220808 ↗ |
| Target | DRD3 | “Dopamine D3 receptor agonist” CHEMBL220808 ↗ |
| Target | DRD4 | “Dopamine D4 receptor agonist” CHEMBL220808 ↗ |
| Target | HTR1A | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL220808 ↗ |